Article
The infection rate was cut in half for the men with the InhibiZone antibiotic covering (1.36% vs. 2.41% in those receiving the untreated prosthesis).
Pivotal data for lumasiran in PH1 published in NEJM
Nedosiran explored in primary hyperoxaluria type 3
Enrollment completed in pivotal trial of nedosiran for hyperoxaluria
FDA approves androgen inhibitor for metastatic PCa
Blood test could guide treatment for kidney cancer
BCG for bladder cancer in short supply
Second-line cabozantinib shows efficacy in advanced renal cell carcinoma
En bloc resection of bladder tumor: Is it the way forward?
Phase 1 study launches of novel CYP11A1 inhibitor for mCRPC
FDA authorizes Expanded Access Program of Anktiva for lymphopenia